23 Jul, 2026
According to Straits Research, the artificial intelligence for drug discovery and development market size was valued at $2.40 billion in 2025 and is estimated to reach $25.35 billion by 2034, growing at a CAGR of 29.9% during the forecast period.
Artificial intelligence (AI) is the application of science and technology to create intelligent devices, particularly intelligent computer programs. AI is a smart system that relates diverse human intelligence-based activities, such as reasoning, learning, and problem-solving, to numerous fields, including biology, computer science, psychology, mathematics, languages, and engineering. AI has applications in the healthcare business for medication management, treatment regimens, and drug research and development, among others.
The drug discovery and development process involves several costly processes and phases. Additionally, clinical studies and market approval of the medicine may be challenging. This industry is primarily driven by increased cooperation between pharmaceutical and biotech businesses and AI service providers. Artificial intelligence reduces the time and money required for medication discovery and development, significantly impacting the market growth. The market expansion is anticipated to be driven by the rising demand for cloud-based software that helps researchers create medications quickly and precisely. Additionally, incorporating artificial intelligence (AI) and machine learning strategies inside the life science R&D business makes medication discovery and development more innovative, efficient, and affordable.
Artificial intelligence is one of the essential technologies, with the pharmaceutical and healthcare industries being the most affected. Numerous healthcare organizations in quest of new technologies have formed partnerships with IT industries that offer artificial intelligence for drug discovery. IT companies use their technology to accelerate the drug discovery and design process by providing novel compounds matched to the characteristics of a pharmacological target using an AI-driven strategy. In June 2018, GlaxoSmithKline (GSK) will cooperate with Cloud Pharmaceuticals to strengthen its drug discovery efforts utilizing artificial intelligence (AI) technologies.
Moreover, in 2018, Pfizer and IBM partnered to expedite immuno-oncology drug discovery. There is a healthy distribution of such partnerships spanning various research fields, including identifying novel small compounds, creating new treatment modalities, and monitoring health data via wearable devices. It is anticipated that these advances will contribute to the progress of healthcare services, the improvement of clinical trial efficiency, and other developments. For example, growing investment by key players in biopharma firms and increasing public and private partnerships for R&D activities with IT industries are likely to drive market expansion.
The pharmaceutical sector has obstacles in overcoming the high attrition rates in drug development. Pharmaceutical and artificial intelligence sectors are partnering to solve obstacles. AI increases the effectiveness of the medication development process. It has been acknowledged that artificial intelligence has vast applications in the field of drug research since it aids in analyzing epidemics, developing remedies for diseases, and predicting which animal viruses tend to change. Artificial intelligence has been shown to improve research and development in drug discovery, enabling scientists to identify new medications for ailments.
In addition, big data can improve the design of clinical trials, develop new drugs, and detect adverse drug reactions. Therefore, artificial intelligence may be a superior alternative that can increase and accelerate the creation of new medications.
Region-wise, the global artificial intelligence for drug discovery and development market is analyzed across North America, Asia-Pacific,
Europe, and LAMEA. North America contributed the most revenue and is projected to expand at a CAGR of 30.8%. North America's market growth is primarily driven by a surge in demand for precision medicine, a sophisticated healthcare infrastructure, and many cross-industry collaborations. In addition, an increase in the adoption of new drug discovery methods and an increase in the number of R&D activities drive the growth of the North American market. The market growth in North America is anticipated to be boosted by the number of collaborations between businesses. In addition, an increase in government attempts to cut overall healthcare costs and improve the quality of healthcare services influences the market's growth in North America.
Europe is the second largest region. It is estimated to reach an expected value of USD 3200 million by 2030, registering a CAGR of 32.4%. Due to the development of algorithms, an increase in the number of acquisitions of small artificial intelligence startups in the region is anticipated to boost the expansion of the European market. In 2014, Google purchased the artificial intelligence startup DeepMind, based in the United Kingdom. Increased investment in European artificial intelligence research and development is anticipated to stimulate market expansion. In addition, the government's substantial support for developing artificial intelligence in medication research contributes to market expansion. Moreover, numerous pharmaceutical businesses and AI companies in Europe are partnering, contributing to the European market's development.
Asia-Pacific is the third largest. The Asian-Pacific market expansion is predicted to be primarily driven by increased government initiatives to strengthen the healthcare sector and investments in foreign companies, mainly U.S.-based companies. Data analytics firm Elucidate, an India and U.S.-based data science startup, has raised $1.7 million in venture funding headed by Hyperplane Venture Capital; the company focuses on developing tools and software for drug discovery. In addition, an increase in significant investments in research and development, the improvement of healthcare infrastructure, and the presence of artificial intelligence provider companies such as iCarbon X, WuXi NextCODE, Huawei, Tencent, Elucidate Corporation, and others, all contribute to the growth of the market in Asia-Pacific. Moreover, many IT businesses are partnering with pharmaceutical companies in the Asia-Pacific region, which is expected to fuel market expansion due to the significant benefits of utilizing artificial intelligence, such as enhanced clinical trials and enhanced drug discovery efficiency. For example, Insilico struck a $200 million artificial intelligence drug discovery agreement with China's CTFH (Chia Tai Fengtai Pharmaceutical) in October 2019, with a primary focus on triple-negative breast cancer targets. The expansion of the Asia-Pacific artificial intelligence in drug discovery is anticipated to be driven by a rise in funding for artificial intelligence improvement.
sales@straitsresearch.com